According to the European Medicines Agency, booster doses can be considered for 18-year-olds and over at least six months after the first dose.
After reviewing data from the Pfizer vaccine, the agency's human medicine committee recommended the recommendation. The data showed an increase in antibody levels 6 months after boosters were administered to people aged 18-55 years.
A third dose of the Pfizer BioNTech or Moderna vaccine should be given to severely weakened patients at least 28 days following their first shot.
According to the agency, the decision was made after research showed that extra vaccines could increase the ability of people to make antibodies against COVID-19. This virus causes organ transplant patients with weak immune systems.
The agency stated in a statement that although there is no direct evidence to support the production of antibodies in these patients, it is possible that an extra dose will increase protection at most in some patients."
Numerous studies have shown that Moderna and Pfizer-BioNTech vaccines are still highly protective for months after the second dose. This dramatically reduces the chance of death or hospitalization.
The chief of the World Health Organization had advised wealthy countries not to use booster shots this year. He said there was no scientific evidence that these shots are needed. He stated that COVID-19 vaccines could be better used in developing countries where many still have not had their first vaccination shots.
The United States government launched last month a campaign to give boosters of Pfizer’s COVID-19 vaccine for millions of Americans, even though federal health officials stressed that the main problem is still getting the first shots to the unvaccinated.
Pfizer BioNTech stated in a statement that it did not expect the introduction in the USA and EU of booster doses to have an impact on existing supply agreements with governments and international organizations in the field of health.
At least 4.8 Million people have been killed by the coronavirus pandemic.